CAR-T cells against CD133, a surface glycoprotein commonly over-expressed in HCC with prognostic value,28 have shown to stabilize HCC in most patients in two phase I/II clinical trials.12,13. The gene discussed is PROM1; the disease is hepatocellular carcinoma.